Active Biotech AB Interim report January - June 2010

August 11, 2010 08:30 (CEST)

·           Laquinimod ― Phase III trials proceeding as planned


·           TASQ ― final Phase II data presented at ASCO. Phase III preparations proceeding on schedule
 

·           ANYARA ― article published in Journal of Immunotherapy


·           57-57 ― exploratory clinical trial under way. Development for treatment of orphan drug indication (systemic sclerosis/scleroderma) initiated


·           ISI ― project continuing according to plan


·           RhuDex(TM) ― preclinical studies completed during the year

 

·           Net sales of SEK 6.1 M (5.2)

 

·           Operating loss of SEK 102.4 M (loss: 118.5)

 

·           Loss after tax SEK 108.3 M (loss: 118.6)

 

·           Loss per share for the period amounted to SEK 1.67 (loss: 2.22)

 

·           The company received approximately SEK 149 M from a directed share issue, cash and cash equivalents at the end of the period amounted to SEK 235 M

 

 

For further information, please contact:

Tomas Leanderson
President and CEO
Tel: +46 (0)46-19 20 95

 

Göran Forsberg                                   
VP Investor Relations & Business Development                          
Tel: +46 (0)46-19 11 54                                        

 

Hans Kolam                                                                         
CFO                                                                       
Tel: +46 (0)46-19 20 44                                                        

 

Active Biotech AB
(Corp. Reg. No. 556223-9227)
PO Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com               

Active Biotech AB Interim report January - June 2010